This reprint contains data from a Genentech-sponsored phase III clinical trial that led to the approval of Genentech's product Cathflo® Activase® (alteplase) 
tinctly different in children from that in adults; children tend to have fewer veins to select from, and the catheters have smaller bores with significantly smaller lumen volumes than do the catheters used in adults. Placement of the access devices often requires coop erative input from pediatricians/neo natologists, anesthesiologists, sur geons, interventionalists, nurses, and parents. Replacement or exchange of an occluded CVAD in a sick child can be a vexing issue resulting in interrup tion of therapy, need for scheduled room time (operating room or angiog raphy suite), repeat operative inter vention, use of general anesthesia, and incremental health care costs to deal with delays and additional proce dures. Therefore, the ability to nonin vasively salvage the dysfunctional CVAD is critically important to mini mize disruption in care and reduce the added risks of additional radiation ex posure, anesthesia, and surgery.
Thrombolytic agents have been used during the past three decades as a potential method to restore flow to occluded CVADs in children; how ever, few prospective studies have been conducted to investigate pre specified techniques and endpoints (2) (3) (4) (5) (6) . Before 1998, the only thrombo lytic agent approved by the U.S. Food and Drug Administration (FDA) for catheter clearance was human-derived urokinase (Abbokinase Open-Cath; Abbott Laboratories, North Chicago, IL). However, the product was with drawn from the market in November 1998 (7) , and no approved product was available until 2001. In September 2001, the FDA approved the use of alteplase (Cathflo Activase; 2-mg/vial, Genentech, South San Francisco, CA) for the indication of restoring function to CVADs as assessed by the ability to withdraw blood (8) . The approval was based on the pivotal phase III Cardio vascular Thrombolytic to Open Oc cluded Lines (COOL) trial (9) and COOL-2 trial (10), but the study pop ulation consisted predominantly of adult patients; patients younger than 2 years of age or with a body weight of less than 10 kg were excluded. Because of the scarcity of safety data in chil dren, the FDA requested that an addi tional postmarketing study be con ducted in pediatric patients (11) . The Cathflo Activase Pediatric Study (CAPS) was conducted to specifically address the safety and efficacy of alte plase in a pediatric population with dysfunctional catheters.
MATERIALS AND METHODS

Objectives
The primary objective of the study was to evaluate safety, as measured by the incidence of intracranial hemor rhage (ICH) documented by com puted tomography (CT) or magnetic resonance (MR) imaging, during the treatment period and within 48 hours after the completion of treatment with alteplase. Two prespecified popula tions were patients 2-16 years of age and those younger than 2 years of age. The secondary objectives were to esti mate the rate of restoration of function to dysfunctional CVADs 30 and 120 minutes after administration of a max imum of two instillations of alteplase and to determine the rate of serious adverse events that occurred within 48 hours of treatment. The serious ad verse events studied included major hemorrhage (defined as severe blood loss [>5 mL/kg] or blood loss result ing in hypotension or requiring trans fusion), thrombosis, embolic events (defined as any serious embolic event including pulmonary or arterial events [eg, stroke, peripheral, or major organ] or cholesterol plaque), sepsis, catheter-related complications, or any other serious adverse event.
Study Design
The study was a phase IV prospec tive, open-label, single-arm, multicenter trial conducted at 42 sites in the United States from April 2002 to May 2003 as a postmarketing study that was requested by the FDA and spon sored by Genentech. The request spec ified that the study consist of at least 250 patients 2-16 years of age and 50 patients younger than 2 years of age (10) . The protocol was approved by the institutional review boards at each site, and written informed consent or assent was obtained by a parent, legal guardian, or patient.
Inclusion criteria.-Patients were el igible if they were in clinically stable condition, less than 17 years of age, and had occlusion, defined as with drawal dysfunction, of a CVAD (in cludes up to a triple-lumen catheter and ports). For patients who weighed 10 kg or more, withdrawal dysfunc tion was defined as inability to with draw 3 mL of blood from the CVAD; for patients who weighed less than 10 kg, withdrawal dysfunction was defined as inability to withdraw 1 mL of blood from the CVAD. If mul tiple lumens were dysfunctional, the investigator chose one lumen for the study and treated the same lumen with study drug throughout the study. The ability to infuse fluids into the lumen at the volume neces sary to instill alteplase was also re quired.
Exclusion criteria.-Patients were excluded if CVAD function was re stored after repositioning, the CVAD was inserted less than 48 hours be fore enrollment, the CVAD was im planted specifically for hemodialysis, there was evidence of mechanical or nonthrombotic occlusion as deter mined by the investigator, the patient was previously enrolled in the study, the patient was treated with any thrombolytic agent within 24 hours of enrollment, the patient was at high risk for bleeding events or em bolic events (ie, recent pulmonary embolism, deep vein thrombosis, endarterectomy, clinically significant right-to-left shunt) in the opinion of the investigator or had a known con dition for which bleeding constituted a significant hazard, or the patient had a known hypersensitivity to alte plase or a component of the formula tion.
Treatment protocol.-Alteplase (Cath flo Activase; Genentech) was pro vided as a sterile vial of lyophilized powder with a concentration after re constitution with sterile water of 1 mg/mL (7). Each vial contains 2.2 mg alteplase (which includes a 10% overfill), 77 mg of L-arginine, 0.2 mg of polysorbate 80, and phosphoric acid for pH adjustment. Patients weighing 30 kg or more were to re ceive 2-mL instillations (2 mg) of al teplase within the catheter lumen, and patients weighing less than 30 kg were to receive instillations of al teplase equal to 110% of the esti mated internal lumen volume of the dysfunctional CVAD (dose rounded to the nearest 0.1 mL, not to exceed 2 mL). Although this was not specified in the protocol, the previous safety study of Cathflo Activase used 10-mL syringes for administration of study medication (10) .
Enrolled patients were eligible for serial treatment with a maximum of two instilled doses of alteplase, each with a maximum dwell time of 120 minutes. Assessment of CVAD func tion occurred 30 minutes after admin istration of each dose. CVAD function was assessed by first attempting aspi ration of blood and, if that was suc cessful, attempting infusion of normal saline solution. Restored function was defined as the ability to withdraw 3 mL blood and infuse 5 mL normal sa line solution in patients weighing 10 kg or more or the ability to withdraw 1 mL blood and infuse 3 mL normal saline solution in patients weighing less than 10 kg. If function was not restored at 30 minutes, another assess ment of function was made at 120 min utes. Patients exited the treatment al gorithm when restoration of CVAD function was established or after as sessment of CVAD function after the 120-minute dwell time for the second instillation, whichever occurred first.
Assessment of safety had two com ponents. All serious adverse events were to be recorded during the treat ment period. Additionally, all serious adverse events were to be elicited from all patients or patients' represen tatives by telephone or in person at 48 hours after completion of the treat ment algorithm. The posttreatment contact for the assessment of safety events occurred 48 -96 hours after completion of the treatment algorithm. An adverse event was defined as seri ous if it resulted in death, was lifethreatening, required or prolonged in patient hospitalization, was disabling, resulted in a congenital anomaly or birth defect, may have jeopardized the patient, or may have required medical or surgical intervention to prevent one of these outcomes. Targeted serious adverse events of specific interest in cluded ICH, major hemorrhage, thrombosis, embolic events, sepsis, and catheter-related complications. Screening CT or MR imaging was not performed on patients to exclude an ICH during the treatment period and within 48 hours of treatment. Adverse events that were not serious were not to be recorded.
Statistical Analysis
Safety and efficacy analyses were based on all enrolled patients who re ceived treatment with alteplase (de fined as the safety-evaluable popula tion). Treatment was recorded as having occurred in patients who re ceived at least one complete or partial instillation of alteplase.
For the primary safety endpoint of ICH, for each of the secondary safety endpoints (major hemorrhage, throm bosis, embolic events, sepsis, and cath eter-related complications), and for the endpoint of any other medically important event, the event rate was calculated and an exact 95% CI was provided. Event rates and correspond ing exact 95% CIs were also calculated for the two subgroups of patients less than 2 years of age and 2 years of age or older.
For the primary efficacy endpoint (cumulative restoration rate of CVAD function after a maximum of two in stillations of alteplase, each with a maximum dwell time of 120 minutes) and for each of the secondary and other efficacy endpoints (restoration rate at 30 minutes after the first instil lation, cumulative restoration rate at 120 minutes after the first instillation, and cumulative restoration rate at 30 minutes after the second instillation), the restoration rate was calculated and an exact 95% CI was provided. The event rates and corresponding exact 95% CIs were also calculated for the two subgroups: patients younger than 2 years of age and those 2 years of age or older. Patients who did not com plete the treatment algorithm were considered to have experienced treat ment failure for purposes of the effi cacy analyses.
All statistical analyses were per formed with SAS software (version 8.2; SAS, Cary, NC). The exact 95% CIs were computed with use of the F dis tribution method provided by Collett (12) .
RESULTS
Demographics
The study population consisted of 310 treated patients (56.1% male and 43.9% female), the majority of whom were white (70.3%), with a mean age of 7.2 years (range, 0.04 -18.3 y) ( Table  1) . Fifty-five patients were younger than 2 years of age, and 255 were 2 years of age or older. The overall mean body weight was 30.3 kg (range, 2.2-107.0 kg); 39 patients (12.6%) weighed less than 10 kg.
The most frequent types of CVAD (in descending order) were a port (51.6%), a double-lumen catheter (30.0%), a single-lumen catheter (14.5%), and a triple-lumen catheter (3.9%). By age stratum, the most common type of CVAD in the younger age group was a double-lumen catheter (49.1%) and the most common type in the older age group was a port (59.2%). The primary indications for catheter placement were chemotherapy administration (69.0%), hydration and/or blood transfusion (56.5%), and antibiotic ad ministration (44.5%).
At the time of study treatment, 55% of patients had catheters implanted for less than 90 days and 24.3% had the implanted device for more than 1 year. The majority of patients (81%) re ceived treatment with study drug on the same day that catheter dysfunction was diagnosed.
All enrolled patients were to re ceive treatment with a maximum of two serially instilled doses of alte plase. Of the 310 enrolled and treated patients, 255 (82.3%) received one dose of alteplase and 55 (17.7%) received two doses. In addition, a total of 282 patients (91.0%) completed the study treatment algorithm and the posttreat ment follow-up assessment.
Protocol Deviations
Of the 310 patients, the treatment of 44 (14.2%) involved one or more major protocol deviations. These consisted of CVAD insertion less than 48 hours be fore enrollment (n = 2), high risk for bleeding or embolic events (n = 2), age greater than 17 years (n = 3), incom plete treatment algorithm (n = 25), and incorrect dose (n = 16). Incorrect dose was defined as administration of a dose of alteplase that was more than 30% greater than the protocolspecified dose or less than 77% of the protocol-specified dose. Overall, the percentage of patients with major pro tocol deviations was roughly equiva lent in the two age strata (14.5% among patients <2 years of age and 14.1% among patients :2 years of age). However, for the group of pa tients younger than 2 years of age, in correct dosing was the most frequent protocol deviation (7.3%), whereas for the older patient group, incomplete treatment algorithm was the most fre quent protocol deviation (9.0%).
Safety Outcomes
The primary safety outcome mea sure was the incidence of ICH docu mented by CT/MR imaging during the treatment period and 48 -96 hours after completion of the treatment algo rithm; however, patients did not un * Defined as the number of days from catheter insertion to treatment. † Defined as the number of days from determination of catheter dysfunction to treatment. ‡ Defined as the ability to infuse 5 mL for subjects weighing :10 kg and 3 mL for subjects weighing <10 kg; presented as number and percentage of subjects with infusion ability. Note.-Values in parentheses are percentages unless specified otherwise.
dergo routine screening CT or MR im aging. No patients experienced an ICH during the study (95% CI, 0%-1.2%). The secondary safety outcome mea sures included the incidence of tar geted serious adverse events (major hemorrhage, thrombosis, embolic event, sepsis, and catheter-related complications) that occurred any time during the treatment period or within 48 -96 hours as determined clinically by the investigator after completion of the treatment algorithm. No cases of major hemorrhage, thrombosis, or em bolic events were reported during the study (95% CI for each event, 0%-1.2%). No deaths occurred during the study or the 48-to 96-hour obser vation period.
Overall, three cases of sepsis were reported (1.0%; 95% CI, 0.2%-2.8%).
All three cases were in patients who were at least 2 years of age and who had preexisting infection. The first case was in a 10-year-old patient being treated for Ewing sarcoma who pre sented with neutropenia, fever/chills, and positive blood culture for Gramnegative bacilli. The patient received alteplase 6 days after admission, and cultures performed on that day were reported to be positive 3 days later. The catheter was then removed, and a culture of the catheter tip revealed an identical organism. This case repre sented the only case of protocol-de fined sepsis. The second case was in a 4-year-old patient with pre-B-cell acute lymphocytic leukemia admitted for fever, neutropenia, fungal sepsis, and renal compromise who had been treated unsuccessfully with alteplase on the day of admission and died of Candida albicans septicemia 15 days af ter study treatment. The third case was in a 13-year-old patient with os teogenic sarcoma in whom progres sive bacterial sepsis developed, which was assessed by the investigator to be related to alteplase administration. The patient was admitted with fever and blood cultures positive for Staph ylococcus species. One day after admis sion, the patient was treated with two doses of alteplase and experienced hy potension requiring pressor support for 2.5 hours after treatment.
Four patients experienced catheterrelated complications (1.3%; 95% CI, 0.4%-3.3%): one patient in the younger age group (1.8%) and three patients in the older age group (1.2%). The first case involved the rupture of the cath eter lumen when it was forcibly in fused with 0.1 mL of study drug in a patient with a 2-year-old Broviac cath eter; this event was assessed by the investigator as related to alteplase administration. For the remaining three cases, no additional details were provided by the reporting in vestigator.
In total, nine serious adverse events were reported in eight patients (2.6%), two of which were assessed by the investigator as related to alteplase ad ministration (one case of sepsis and one case of a ruptured catheter lu men). These included the four cases mentioned previously and one case of each of the following: fever, tumor lysis syndrome, convulsions/sei zures, anxiety attack, and cardiomy opathy.
Efficacy Outcomes
The primary efficacy outcome mea sure was the overall (ie, cumulative) rate of restoration of CVAD function after serial administration of a maxi mum of two instillations of alteplase, each followed by a maximum 120 minute dwell time. The overall rates of restoration of catheter function at 30 and 120 minutes were 53.5% and 75.2% and 80.3% and 82.9%, respec tively, after the first and second doses. Outcomes were similar among all sub groups (sex, age, CVAD type, body weight) (Table 2; Figure) . Note.-Values presented are the number (percentage) of subjects in the subgroup with restored function at or before the specified time point. * If multiple lumens were dysfunctional, the investigator chose one lumen for the study; in this case, restoration of function refers to one lumen only.
DISCUSSION
The management of dysfunctional vascular accesses in sick children can be frustrating and can use significant resources from multiple caregivers, ranging from the primary physician and nursing staff to surgeons, radiol ogists, anesthesiologists, and phlebot omy/infusion teams. Instillation of a thrombolytic agent has been used in pediatric practice as a noninvasive method to salvage occluded catheters, and numerous retrospective singlecenter reports have been published, but there are few multicenter, prospec tive data from larger clinical trials.
Alteplase has been approved by the FDA for the restoration of function to occluded CVADs on the basis of the phase III COOL trials involving 1,135 treated patients (9, 10) . A total of 126 patients (11%) were 2-16 years of age, and no study drug-related adverse events were reported in this age group. However, there was insuffi cient enrollment of pediatric patients to enable any firm conclusions to be drawn regarding relative efficacy in the pediatric or low-weight sub- groups, relative efficacy related to thrombolytic agents typically involves catheter types used, or relative rates of the instillation and filling of the entire adverse events (8) .
dysfunctional catheter lumen with Catheter clearance with use of thrombolytic drug. In children, cathe ter lengths are variable and are cus tomized by the implanting physician or nurse depending on the anatomy and size of the patient. The lumen vol umes are often not precisely known. Instillation of alteplase in the CAPS trial involved slight overfilling of the estimated lumen volume (110%) in children weighing less than 30 kg and a 2-mg dose (2 mL) in all catheters in children weighing 30 kg or more. A small amount of alteplase may have been administered into the systemic circulation. When alteplase is admin istered according to the study proto col, any circulating plasma levels of alteplase are not expected to reach pharmacologic concentrations (13) . The most frequent complication of systemic thrombolysis is bleeding, of which ICH represents the most severe adverse event. The main objective of the current study was to assess the overall safety of a maximum of two instilled doses of alteplase in children.
The results of this study showed that the treatment protocol is safe in children. No pediatric patient experi enced ICH, major hemorrhage, throm bosis, or embolic event. In comparison with the COOL trials (9,10), the rates of serious adverse events were similar in pediatric and adult patients.
The most common serious adverse event reported in CAPS was sepsis (1%; n = 3). All these patients had evidence of infection before adminis tration of alteplase. Alteplase or any thrombolytic agent should be used with caution in the presence of a known or suspected infection in the catheter. Because evaluation of the catheter involves instillation and flushing, the technique may release a localized infected clot or nonthrom botic debris into the systemic circula tion.
The cumulative restoration rates observed in CAPS are similar to those observed in the COOL studies (9, 10) . The cumulative restoration rates re ported in the COOL-2 study (10), which used an identical treatment reg imen in 995 patients, were 52% and 75% at 30 and 120 minutes after one dose and 82% and 85% after a second dose, respectively. In this trial, the cu mulative restoration rates were 54% and 75% at 30 and 120 minutes after one dose and 80% and 83% after a second dose, respectively. These find ings are similar to those of a 2001 re port in which alteplase was used to treat 228 children with 320 central ve nous catheter occlusions (6) . In this study, patency was restored in 91% of catheters after one to three treatments. In the current study, the ability for alteplase to restore function was simi lar among all subgroups, including those based on age, body weight, and catheter type. Therefore, these factors do not appear to play a significant role in the restoration of patency to the occluded catheter.
The CAPS has certain limitations. Treatment of hemodialysis catheters was not evaluated, and therefore the study findings should not be trans lated to patients with occlusion of these devices. Bamgbola et al (14) have previously noted that low-dose, shortduration alteplase infusions were safe and effective for catheter thrombolysis in children with occluded hemodialy sis catheters. In addition, the current study did not examine the use of alte plase for the simultaneous treatment of multiple catheter lumens. Future studies should assess the safety and efficacy of alteplase in patients with multiple-lumen catheter occlusion. In addition, use of shorter or longer alte plase dwell times, including "locking" the catheter with alteplase instead of heparin as a means for prophylactic maintenance of patency in trouble some devices, also was not evaluated (15) . Although Weck et al (15) recently reported that 90% of thrombolytic ac tivity was maintained 7 days after al teplase reconstitution with sterile wa ter for injection, further evaluation is warranted before alteplase can be rec ommended as a locking solution. An incomplete treatment algorithm (caused by missed assessment or missed dose) occurred in 25 patients (8.1%), and incorrect dosing occurred in 16 patients (5.2%). Although these patients were included in the analysis, these results are unlikely to affect the overall efficacy, because an incom plete treatment algorithm would likely decrease the efficacy as underdosing would. Finally, another limita tion of this study is that the volume of Cathflo Activase administered fre quently exceeded that of the catheter lumen volume (especially in patients weighing <30 kg), which could have resulted in mechanical dislodgement of the catheter occlusion. However, because the efficacy was similar to that observed in the COOL-1 study (9) , which was placebo controlled, this is unlikely to have affected the observed efficacy rates.
On the basis of the overall data sub mitted, the FDA reviewed and amended the prescribing information for Cathflo Activase to include this clinical study (8) . In conclusion, the trial results support that the use of alteplase is safe and effective in the restoration of function to occluded CVADs in children and infants.
